Shares of Gilead Sciences, Inc. (GILD) tumbled 2.2% on Aug. 21, after pharmacy benefit manager CVS Health (CVS) decided not ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Kenya is one of nine African countries selected for the initial rollout of lenacapavir (LEN), a new injectable drug for human ...

Studies done in various countries, including South Africa, have shown that lenacapavir is highly effective for HIV prevention.

Ian L. Haddock, founder of the Normal Anomaly Initiative, participated in the trials for lenacapavir, an FDA-approved drug ...

Advocates for HIV prevention are calling a newly approved injectable medication a major step in eliminating the spread of the ...

Access is the central tenet to the success of lenacapavir as a form of preexposure prophylaxis (PrEP), according to Jeremiah Johnson, the executive director of PrEP4All and Mitchell Warren, the ...

What is lenacapavir and how does it work? Lenacapavir is a medicine used to help prevent and treat HIV. It works by blocking the outer shell, or “capsid,“ that the virus needs to protect itself.

Lenacapavir is given in two injections that have to be delivered subcutaneously, something that “takes training and time” to learn, National Institute of Allergy and Infectious Diseases ...

For lenacapavir, 100% efficacy for HIV prevention in women in PURPOSE 1 [NCT04994509], 96% [reduction in risk of HIV] in men and gender diverse people [in PURPOSE 2].

“Lenacapavir helps to fill a critical unmet need for people with complex prior treatment histories and offers physicians a long-awaited twice-yearly option for these patients who are at greater ...

Lenacapavir is being developed as a foundation for potential future HIV therapies with the goal of offering both long-acting oral and injectable options with several dosing frequencies, in ...